New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
10:44 EDTCVX, UAL, ALK, JBLU, RDS.A, SKYW, AMR, HA, BP, XOM, LCC, DAL, LUVGas prices reach record for this time of year, Washington Post reports
Gasoline prices have increased 45c per gallon in the last 31 days, AAA reported, according to The Washington Post. Gas prices have reached an all-time record for this time of year, the newspaper quoted an AAA spokesman as saying. Reference Link
News For A;CVX;BP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
May 18, 2015
07:56 EDTCVXKosmos provides update on Mauritania drilling
Subscribe for More Information
07:23 EDTCVXChevron downgraded to Sell from Neutral at Goldman
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
06:44 EDTBP, CVXEnvironmentalists file lawsuit over oil train safety rules, NY Times says
Subscribe for More Information
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
May 12, 2015
05:38 EDTBPTechnip awarded lump sum project by BP Exploration & Production
Subscribe for More Information
May 11, 2015
13:28 EDTCVX, BPOPEC sees oil at around $76 a barrel in 2025, WSJ says
Subscribe for More Information
May 8, 2015
18:09 EDTBPCourt says BP can appeal some Gulf spill damages claims, Reuters reports
A U.S. federal appeals court said BP should be allowed to appeal some damage claims awarded to those in connection with the 2010 Gulf of Mexico oil spill, Reuters reports. The decision by the 5th U.S. Circuit Court of Appeals in New Orleans may help BP limit its payout to victims of the Deepwater Horizon drilling rig explosion, Reuters added. Reference Link
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use